HNC364 vs Safinamide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: MAO-B · full Parkinson's Disease pipeline
HNC364
Developed by Guangzhou Henovcom Bioscience Co. Ltd.
NCT05523570 · Phase 1 · completed
Participants were not randomized and neither they nor the investigators were blinded, and there was no placebo or comparator group, so this design cannot separate a real drug effect from chance, natural variation, or expectation. Results have not yet been posted.
Next expected readout: December 2026 · NCT06798519 (registry estimate)
No aligned efficacy figure on record for this race.
Safinamide · Xadago
Marketed by Supernus Pharmaceuticals and partners
NCT00605683 · Phase 3 · completed
The study was randomized and double-blind, included 679 participants, and compared two safinamide doses with placebo. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: December 2027 · NCT07761936 (registry estimate)
Reported efficacy
Change From Baseline to Week 16 in the Mean Total Daily "OFF" Time (At baseline and Week 16): Change From Baseline to Week 16 in the Mean Total Daily "OFF" Time (At baseline and Week 16): Safinamide -1.93 Hours (Standard Deviation 2.556) vs Placebo -0.88 Hours (Standard Deviation 2.543) (met)
Result source: NCT03881371
Results for Parkinson's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | HNC364 | Safinamide |
|---|---|---|
| OFF time, change | —Not reported | -1.9 vs -0.9−1 vs placeboNCT03881371 |
| ON time without troublesome dyskinesia, change | —Not reported | —Not posted · NCT00643045 |
| UPDRS Part III, change | —Not reported | —Not posted · NCT00643045 |
| MDS-UPDRS Part II, change | —Not reported | —Not posted · NCT00643045 |
OFF time, change
- HNC364
- —Not reported
- Safinamide
- -1.9 vs -0.9−1 vs placeboNCT03881371
ON time without troublesome dyskinesia, change
- HNC364
- —Not reported
- Safinamide
- —Not posted · NCT00643045
UPDRS Part III, change
- HNC364
- —Not reported
- Safinamide
- —Not posted · NCT00643045
MDS-UPDRS Part II, change
- HNC364
- —Not reported
- Safinamide
- —Not posted · NCT00643045
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
HNC364: no structured comparison results are available for Parkinson's Disease.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. HNC364: 0 of 4 rows · Safinamide: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Safinamide |
|---|---|
| Dropout rate | 10.5%a NCT03881371 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 show 2 more results19.4%100 mg NCT05312632 · Phase 4 · registry result, not featured evidence · add on 17.4% NCT03841604 · Phase 4 · registry result, not featured evidence |
| Discontinued due to AEs | 5.2%a NCT03881371 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 show 2 more results6%100 mg NCT05312632 · Phase 4 · registry result, not featured evidence · add on 8.7% NCT03841604 · Phase 4 · registry result, not featured evidence |
| Serious AEs | 5.3%a NCT03881371 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 show 2 more results2%100 mg NCT05312632 · Phase 4 · registry result, not featured evidence · add on 0% NCT03841604 · Phase 4 · registry result, not featured evidence |
| Most frequent reported AEs | a dyskinesia 11.9% (placebo 3.9%) back pain 6% (placebo 3.9%) dizziness 6% (placebo 6.5%) NCT03881371 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 show 2 more results100 mg overdose 6.5% dyskinesia 5.5% covid-19 2.5% NCT05312632 · Phase 4 · registry result, not featured evidence · add on constipation 6.5% (placebo 0%) back pain 4.3% (placebo 0%) dyskinesia 4.3% (placebo 0%) NCT03841604 · Phase 4 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 2 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Safinamide
show 2 more results
show 1 more result
show 1 more result
+ 9 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HNC364's landscape · Safinamide's landscape